Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

21.81 -0.18 (-0.82%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug ↗

July 31, 2025

Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from...

Via Stocktwits

Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗

July 31, 2025

Via Benzinga

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss ↗

July 31, 2025

Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for...

Via Chartmill

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

July 31, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio ↗

July 29, 2025

FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits.

Via Benzinga

Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals ↗

July 28, 2025

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.

Via Stocktwits

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

July 28, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

July 24, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals's Earnings Outlook ↗

May 06, 2025

Via Benzinga

Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views ↗

March 03, 2025

Via Benzinga

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) ↗

July 18, 2025

Via Benzinga

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

July 15, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

July 02, 2025

Via Benzinga

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

July 01, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

June 06, 2025

From Apellis Pharmaceuticals, Inc.; Sobi

Via GlobeNewswire

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 04, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts ↗

May 22, 2025

Via Benzinga

Why Apellis Pharmaceuticals Wilted on Wednesday ↗

May 07, 2025

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

May 07, 2025

Via Benzinga

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 07, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

May 06, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

April 30, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

April 29, 2025

Via Benzinga

Apellis Announces Craig Wheeler to Join the Board of Directors

April 21, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗

April 01, 2025

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Via Benzinga

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

April 01, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗

March 18, 2025

JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.

Via Benzinga

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst ↗

March 05, 2025

JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.